Kornimate/medical-research-clean huggingface dataset:
immune microenvironment and gene expression profiling in mesothelioma

Conditions: Mesothelioma; Mesotheliomas Pleural; Mesothelioma; Lung

Summary: pleural and peritoneal mesotheliomas (ppm) are rare cancers mostly related to asbestos-exposure, which are characterized by a complex histopathological diagnosis and staging, few therapeutic options and a dismal prognosis. the main unmet medical need in ppm is the lack of a treatment sequence for affected patients. the advent of immune checkpoint inhibitors has changed the first line treatment of ppm, thanks to the improvement in survival achieved by the combination of ipilimumab and nivolumab that are currently approved for non-epithelioid histology in our country. ppm is characterized by a large heterogeneity of the genomic landscape, which is mainly characterized by the loss of tumour suppressor genes and mutations in dna repair genes and by an "altered- suppressed" or "excluded" tumor immune microenvironment (time). the goal of this project is to improve the immune-biological and molecular stratification of ppm subgroups that can lead to the identification of different personalized treatment approaches. ppm patients (n=220) will be retrospectively (n=150) and prospectively (n=70) recruited from the coordinator center and 6 participating italian centers. treatment-naïve tumor samples will be collected and analyzed by bulk gene expression and spatial whole transcriptome analysis, and by 9-color multiplex immunofluorescence. new targets or actionable pathways potentially emerging from such studies will be finally assessed and validated in patient-derived organoids/xenografts that accurately reflect ppm tumorigenesis.


Eligibility criteria:
inclusion criteria: * patients with mesothelioma of the pleura and peritoneum * age greater than 18 years of age * patients undergoing surgery will require both biopsy and surgical sampling material * pathologist's confirmation of the presence of tumor sections in the excised specimens * patients in follow-up from active cancer treatment for at least 6 months exclusion criteria: * inadequacy of biological material for analysis under study * patients not amenable to active oncologic treatment * patients lost to follow-up before 6 months after the end of active oncologic treatment

Keywords: pleura mesothelioma ppm patients lung gene expression profiling immune microenvironment
single-session computerized mental health intervention for rural indian adolescents

Conditions: Well-Being; Depression; Anxiety

Summary: the overall aim of this project is to understand if single-session interventions are acceptable, culturally appropriate, and effective for indian adolescents attending a rural, low-resource government school. the investigators will be examining the effects of a computerized intervention on the well-being and mental health of adolescents. the investigators hypothesize that the intervention will yield statistically significant improvements in wellbeing and mental health relative to a study skills control condition.


Eligibility criteria:
inclusion criteria: * attending a participating secondary school * age 12 to 18 * literate in english exclusion criteria: * unable to provide informed consent
role of interleukin-1 in postprandial fatigue - the cheesecake study

Conditions: Postprandial Fatigue

Summary: the aim of the study is to investigate, if postprandial fatigue symptoms after ingestion of a high-fat, high-carbohydrate meal are regulated by interleukin (il)-1 and can be prevented by inhibition of il-1 using a single dose injection of a specific il-1 receptor antagonist.


Eligibility criteria:
inclusion criteria: * male * non-smoking * apparently healthy * bmi \>18 and ≤25 kg/m2 * age 20-50 years * willingness to use contraceptive measures adequate to prevent the subject's partner from becoming pregnant during the study. adequate contraceptive measures include hormonal methods used for two or more cycles prior to screening (e.g., oral contraceptive pills, contraceptive patch, or contraceptive vaginal ring), double barrier methods (e.g., contraceptive sponge, diaphragm used in conjunction with contraceptive foam or jelly, and condom used in conjunction with contraceptive foam or jelly), intrauterine methods (iud), sterilization (e.g., tubal ligation or a monogamous relationship with a vasectomized partner), and abstinence. exclusion criteria: * clinical signs of infection in the week before inclusion or history of infection during the last 2 months (crp \>5mg/l) * impaired fasting glucose (fasting plasma glucose \>5.5mmol/l) * hematologic disease (leukocyte count \< 1.5x109/l, hemoglobin \<11 g/dl, platelets \<100 x 103/ul) * kidney disease (creatinine \> 1.5 mg/dl)) * liver disease (transaminases \>2x upper normal range) * heart disease * pulmonary disease * inflammatory disease * history of carcinoma * history of tuberculosis * alcohol consumption \>40g/d * smoking * known allergy towards anakinra * known allergy towards ingredients of the test meal * current treatment with any drug in the week before inclusion, including vitamin supplementation (especially vitamin c and e) * use of any investigational drug within 30 days prior to enrollment or within 5 half-lives of the investigational drug, whichever is longer * subject refusing or unable to give written informed consent

Keywords: fatigue
central programming in patients with a bionic hand after traumatic brachial plexus injury

Conditions: Brachial Plexus Neuropathies; Traumatic Brachial Plexus Lesion; Bionic Hand Reconstruction

Summary: traumatic brachial plexus lesions may lead to permanent impairment of hand function despite brachial plexus surgery. in selected cases the affected forearm can be amputated and replaced by a bionic hand. it is unclear how cortical activation patterns change after the injury and after acquisition of the hand prosthesis considering the complex changes in sensory and motor feedback. the aim of the study is to measure cortical activity with fmri during actual and imagery movements with the affected and healthy arm in a group of patients after traumatic brachial plexus injury and a group in whom this was followed by replacement with a bionic hand. in this prospective study three groups of patients will participate: 1) 3 adult patients with a traumatic brachial plexus lesion eligible for a bionic arm but prior to its acquisition, 2) 3 patients with a traumatic brachial plexus lesion who have acquired the bionic arm already, and 3) 10 healthy subjects. the investigators will measure cortical activity using fmri bold tasks of closing the hand and motor imagery of this movement. cortical activity will be compared between the three groups. additionally, regional gray matter volume, resting-state, and dti networks will be studied. written informed consent will be provided prior to the investigation. the complete examination has a duration of approximately 45 minutes.


Eligibility criteria:
inclusion criteria: * age above 18 years * participants should understand german or english * patients with a bionic hand are selected who are able to open and close the hand prosthesis. exclusion criteria: * the standard contraindications for mri will be checked for according to hospital protocol (ferromagnetic devices such as clips, claustrophobia, etc.) and, if necessary, patients will be excluded from participation.

Keywords: traumatic brachial plexus lesion bionic hand reconstruction hand amputation hand prosthesis central programming fmri resting state networks dti
treatment resistant epilepsy and n-acetyl cysteine

Conditions: Autistic Disorder; Seizures; Irritability

Summary: this is a study to find out whether the dietary amino acid supplement, n-acetyl cysteine (nac) is helpful in reducing the frequency of seizures in children with autism and comorbid epilepsy whose seizures are not responding well to usual medical treatment. the study is also looking to see if this supplement is helpful for immediate and ongoing treatment of symptoms of irritability. additionally, this study will also look to see if certain substances in the blood that measure a specific type of stress on cells in the body can help tell us how nac may be helping.

one third of patients with idiopathic autism have treatment resistant epilepsy, associated with earlier onset of seizures. in addition to insufficient response to medical treatment, they also have poorer responses to surgical and vns approaches (sansa et al 2011). novel approaches to reduce seizure burden and improve quality of life for the children and their caregivers are needed. there is a plethora of basic research documenting elevated oxidative stress in animal models of seizures. several animal models have decreased oxidative stress through using compounds with antioxidant effects, but suprisingly, few human studies have been done to date. this small open-label pilot study will examine the use of n-acetyl cysteine, an inexpensive but readily available over-the-counter nutritional supplement, to reduce seizure frequency in 10 youth with autism who have not responded completely to conventional anticonvulsant therapy

Eligibility criteria:
inclusion criteria: 1. children and adolescents/young adults ages 6-21, male or female, all races and ethnicities. 2. autism 3. iq less than 80 4. 10 subjects with treatment resistant generalized epilepsy as defined by trials of 3 or more anticonvulsants with continued seizure frequency of at least 1 per week, need to use a helmet, or vagal nerve stimulator placement. 5. children with at least 1 grand mal/generalized seizure per week. exclusion criteria: 1. inability to swallow capsules 2. in females, pregnancy or sexual activity 3. daily acetaminophen, glucocorticoid, or nonsteroidal anti-inflammatory drugs, or daily nac or high-dose antioxidant vitamin supplements within 30 days of baseline. 4. history of acute or chronic liver, renal, endocrine, infectious, autoimmune, hematologic, metabolic, or other disorder in the judgement of the study physician.

Keywords: n-acetyl cysteine refractory seizures
effect of iv iron isomaltoside on postoperative anemia in total knee arthroplasty patients

Conditions: Anemia; Knee Arthropathy

Summary: postoperative anemia is a frequent complication after total knee arthroplasty, with an incidence of 87%. iron supplementation is known to be effective in treatment and prevention of postoperative anemia. the investigators examined the effect of intravenous iron isomaltoside (monofer®) administration on postoperative anemia and transfusion requirements in patients undergoing total knee arthroplasty. participants undergoing total knee arthroplasty will be randomly assigned to treatment group or control group. after main procedure of total knee arthroplasty, iron isomaltoside 1000 (monofer®) or normal saline will be intravenously administered depending on the group assigned. the dose of iron isomaltoside will be determined based on patient's body weight using the manufacturer's recommendation. serum hemoglobin, hematocrit, iron, ferritin, transferrin saturation, and phosphorus level will be checked at preoperative day, postoperative day 1, 7, and 30. the primary outcome is the incidence of postoperative anemia at 30 days after surgery. secondary outcomes included the incidence and amount of red blood cell transfusion during admission period, hospital length of stay, the incidence of surgical site infection, and quality of life during postoperative period.


Eligibility criteria:
inclusion criteria: * adult patients undergoing total knee arthroplasty exclusion criteria: * bilateral total knee arthroplasty * hematochromatosis or hemosiderosis * hemolytic anemia * history of drug allergy * liver cirrhosis or hepatitis * systematic lupus erythematosus * rheumatic arthritis * allergic disease * history of transfusion within one month from surgery * parturient
mechanism underlying the link between hearing loss and cognition

Conditions: Hearing Loss, Bilateral (Causes Other Than Tumors)

Summary: the goal of this clinical trial is to learn if hearing devices, like hearing aids and cochlear implants, affect social and cognitive function of older adults. the main questions the researchers want to answer are: * how social are older adults with hearing loss before and after using hearing devices? * how well do older adults with hearing loss think before and after using hearing devices? * for older adults who have hearing loss and use hearing devices, do changes in social interaction explain changes in how well they think (cognitive function)? * do brainwaves (eegs) in older adults with hearing loss change after using hearing devices? * are there differences in how social older adults with hearing loss are compared to older adults without hearing loss? what participants will do: * participants will take questionnaires for around 60 minutes. questionnaires will ask participants about their background, health, hearing, and how social they are. another set of questionnaires will check their thinking ability or cognition. * participants will wear an audio sensor for 2 weeks. the sensor will collect and store information about a participant's voice during conversations. once the device has information about a participant's voice such as pitch and tone it will store this information and delete the audio recording. words spoken during conversations will be deleted. * (optional) participants can choose to participate in a 45-60-minute eeg (electroencephalogram) recording session. participants will have sensors placed on top of their heads. sensors will record the participants' brainwaves. sounds will be played to see how participants' brainwaves change when they hear sounds.


Eligibility criteria:
inclusion criteria: * age \>= 50 years * english or spanish speaking * individuals who were diagnosed with bilateral hearing loss or healthy volunteers without hearing loss exclusion criteria: * age \<50 years * unable to understand english or spanish

Keywords: hearing loss hearing aids cognition dementia
bcma car-t versus asct in transplant-eligible patients with multiple myeloma

Conditions: Multiple Myeloma

Summary: this is a prospective, non-inferiority study comparing vrd±d followed by bcma car-t cell therapy versus vrd±d followed by autologous hematopoietic stem cell transplantation in the treatment of newly diagnosed multiple myeloma patients.


Eligibility criteria:
inclusion criteria: 1. be informed and voluntarily sign the informed consent form (icf). 2. age between 18 and 70 years (inclusive). 3. have measurable disease meeting at least one of the following criteria: serum m-protein ≥1 g/dl (\>10 g/l) as detected by serum protein electrophoresis (spep), or quantifiable iga or igd levels for iga or igd-type myeloma; urine m-protein ≥200 mg/24 hours; in cases where serum and urine m-protein do not meet the above thresholds, an abnormal free light chain (flc) ratio (normal range: 0.26 to 1.65) and involved serum flc ≥100 mg/l. 4. confirmed expression of the bcma target antigen on mm cells by flow cytometry or bone marrow immunohistochemistry. 5. assessed by the investigator as transplant-eligible. exclusion criteria: 1. primary plasma cell leukemia. 2. concurrent amyloidosis. 3. involvement of the central nervous system (cns). 4. previous treatment with bcma-targeted therapy or car-t cell therapy.
erector spinae plane block impact on quality of recovery after lumbar spinal decompression

Conditions: Postoperative Pain

Summary: erector spinae plane block (espb) as a new trunk fascia block technique was proposed in 2016. espb has aroused the interest of many nerve block experts. the benefits of espb are not yet demonstrated. the specific mechanism is still controversial. some believe that espb can block the posterior root of the spinal nerve and produce part of the para-spinal block effect with the diffusion of the drug solution. the present study will carried out to compare the performance of the erector spinae plane block combined with general anesthesia in addicts versus non addicts' patients regarding the local analgesic effect, recovery after surgery and side effects.


Eligibility criteria:
inclusion criteria: 1. male gender. 2. age range of 18-60 years. 3. scheduled for open lumbar decompression surgery. 4. a minimum of 1-year experience of drug consumption or having drug withdrawal symptoms when stopping for inclusion in the drug addicts group(according to the patient's statement and rapid opiate urine test). exclusion criteria: 1. hepatic or renal insufficiency. 2. preoperative cognitive dysfunction or communication disorder. 3. allergy to amide-type local anaesthetics. 4. back puncture site infection. 5. coagulation disorders. 6. emergency surgery.

Keywords: lumber surgery postoperative analgesia erector spinae pain block
angio-seal evolution device registry

Conditions: Peripheral Vascular Disease; Coronary Artery Disease; Peripheral Artery Disease; Arterial Occlusive Disease; Coronary Heart Disease

Summary: collect data on the use of the angio-seal evolution device in diagnostic and interventional patient populations.

this multi-center clinical registry is designed to collect data on the use of the angio-seal evolution device in patients who have had diagnostic and/or interventional procedures through femoral artery access. data will be collected on a patient's initial screening through hospital discharge and 30 days post-procedure to evaluate major and minor vascular complications as defined in the protocol.

Eligibility criteria:
inclusion criteria: * patient is having a diagnostic and/or interventional procedure via femoral artery access. exclusion criteria: * patients who are unable to provide written informed consent.

Keywords: angio-seal peripheral vascular disease vascular closure device arterial closure coronary artery disease arterial hemostasis coronary cardiac catheterization percutaneous coronary intervention interventional catheterization diagnostic catheterization common femoral artery manual compression vascular intervention angiogram coronary intervention coronary angioplasty angiography arteriotomy vascular access
effects of vagus nerve pulmonary branch block on postoperative cough after vats lung resection

Conditions: Postoperative Cough; Thoracoscopy; Pulmonary Resection; Vagus; Nerve Block

Summary: postoperative cough after pulmonary resection is a common issue seen after thoracic surgeries, hindering patients' recovery and affecting their postoperative quality of life. while vagus nerve pulmonary branch block has been known to reduce intraoperative coughing, its impact on postoperative cough post lung resection is uncertain. this study aims to assess the effects of vagus nerve pulmonary branch block on postoperative cough after vats lung resection. a randomized controlled trial involving 104 thoracoscopic lung resection patients will assign them randomly to a vagus nerve pulmonary branch block group or a control group. the primary outcome measure is the postoperative cough incidence 3 weeks after lung resection. the secondary outcomes include assessing hoarseness in pacu, peak expiratory flow (pef) on the first post-op day, nrs scores for cough, and lcq-mc scores at 3 weeks post-surgery, as well as cough occurrence, nrs scores, and lcq-mc scores at 8 weeks post-procedure.


Eligibility criteria:
inclusion criteria: * age between 18 and 70 years old. * bmi between 18 and 30 kilograms per square meter (kg/m²). * asa physical status classification of i, ii, or iii. * preoperative pulmonary imaging demonstrating peripheral lesions, with clinical staging t≤2, n≤1, m0. * undergone thoracoscopic lung resection surgery. * patients managed by the same lead surgeon's team. * obtained informed consent, with patients agreeing and signing the informed consent document. exclusion criteria: * patients with a history of chemotherapy or previous pulmonary surgery. * presence of chronic cough due to respiratory infectious diseases, pharyngitis, rhinitis, copd, asthma, post-nasal drip syndrome, etc. * individuals exhibiting ecg abnormalities such as atrial fibrillation, bundle branch block, frequent ventricular premature beats, pre-excitation syndrome, etc. * currently using ace inhibitor medications. * presence of preoperative hoarseness.

Keywords: chronic cough postoperative cough thoracoscopy or video-assisted thoracoscopic surgery pulmonary resection or lung resection vagus
esophageal motility in eosinophilic esophagitis evaluated by high resolution manometry.

Conditions: Eosinophilic Esophagitis

Summary: esophageal motility in eosinophilic esophagitis will be evaluated by high resolution manometry before and after medical treatment - motility is suspected to change/improve after therapy.

after identification of eosinophilic inflammation of the esophagus -\> differentiation between gerd and eosinophilic esophagitis (via ph/mii-measurements or ppi-trial) -\> high-resolution manometry (hrm) for evaluation of esophageal motility in patients with eosinophilic esophagitis (exclusion of gerd-patients)-\> initiation of budesonide-therapy -\> after eight weeks of therapy reevaluation of esophageal motility by hrm

Eligibility criteria:
inclusion criteria: • patients with eosinophilic inflammation of the esophagus exclusion criteria: * refusal to participate in study * pregnancy * eosinophilic gastroenteritis * achalasia * contraindication for gastroscopy / hrm / 24-h-ph/impedance-monitoring * contraindication for therapy with budesonide * eosinophilic inflammation due to gerd

Keywords: eosinophilic esophagitis (eoe) gerd esophageal motility
effect of muscle and skin fixation of thoracic drainage tube on postoperative pain

Conditions: Lung Neoplasms; Lung Cancer; Pulmonary Neoplasm; Postoperative Pain; Thoracoscopic Surgery

Summary: lung cancer is the leading cause of cancer-related death worldwide. thoracoscopic pulmonary resection is a prevalent management for early stage of lung cancer. placement of chest tube is the standard procedure after surgery, which causes pain that cannot be ignored. the investigators aimed to determine whether a muscle layer fixation of thoracic drainage tube could release postoperative pain in patients with uniport thoracoscopic pulmonary resection compared with conventional skin fixation.


Eligibility criteria:
inclusion criteria: * 18\<age\<80; * asa≤iii * patients with no clinically significant cardiac history, such as ischaemic heart disease, valvular heart disease, rhythm disturbances such as frequent atrial fibrillation or premature ventricular contractions (pvcs). patients with significant cardiac history should be optimized according the relevant guidelines before surgery is considered. * normal cardiopulmonary function \[predicted forced expiratory volume in the first second(fev1%) \>50% and ejection fraction (ef) \>50%of predicted value\]. resting blood gas analysis showing arterial partial pressure of oxygen (pao2)≥75 mmhg and arterial partial pressure of carbon dioxide (paco2) \<45 mmhg; exclusion criteria: * history of ipsilateral surgery and other conditions which can result in extensive pleural adhesion; * coagulopathy, hypoxemia (pao2 \ 50 mmhg\]; * significant cardiac history.

Keywords: chest tube drainage thoracic drainage thoracoscopic surgery postoperative pain